Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.31 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20314540 | 0.83 | PDE4A (0.37) | SIGMAR1POLBSMN1; SMN2CXCR4CHRM5 | |
| SCHEMBL14614393 | 0.77 | SIGMAR1 (0.37) | SIGMAR1ALDH1A1HTTPOLBSMN1; SMN2 | |
| SCHEMBL5858718 | 0.75 | SIGMAR1 (0.40) | SIGMAR1ALDH1A1HTTPOLBSMN1; SMN2 | |
| SCHEMBL20333626 | 0.75 | SIGMAR1 (0.36) | SIGMAR1ALDH1A1HTTPOLBSMN1; SMN2 | |
| SCHEMBL5858713 | 0.75 | SIGMAR1 (0.40) | SIGMAR1ALDH1A1HTTPOLBSMN1; SMN2 | |
| SCHEMBL19466429 | 0.75 | CYP2D6 (0.38) | SIGMAR1ALDH1A1HTTPOLBSMN1; SMN2 | |
| SCHEMBL104919 | 0.75 | ADRB1 (0.33) | SIGMAR1 | |
| SCHEMBL3888868 | 0.75 | ADRB1 (0.33) | SIGMAR1 | |
| SCHEMBL19139233 | 0.74 | GNAO1 (0.30) | — | |
| SCHEMBL8501828 | 0.73 | SIGMAR1 (0.39) | SIGMAR1ALDH1A1HTTPOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180071262-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071262-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, HDAC9 | SIGMAR1 2184/4885ALDH1A1 601/4885HTT 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.